Felicetto Ferrara

Summary

Country: Italy

Publications

  1. ncbi request reprint Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation
    Franco Leoni
    Divisione di Ematologia, Policlinico di Careggi, Viale Morgagni 85, 50134 Florence, Italy
    Haematologica 87:485-9. 2002
  2. ncbi request reprint High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy
    Br J Haematol 128:234-41. 2005
  3. ncbi request reprint Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
    Roberto Cairoli
    Division of Hematology, Ospedale Niguarda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy
    Blood 107:3463-8. 2006
  4. ncbi request reprint Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, A Cardarelli Hospital, Naples, Italy
    Hematol Oncol 24:73-7. 2006
  5. ncbi request reprint Clinically useful prognostic factors in acute myeloid leukemia
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Crit Rev Oncol Hematol 66:181-93. 2008
  6. pmc Physician's Attitude Towards Treatment of Older Patients and the Choice of Therapy
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Mediterr J Hematol Infect Dis 5:e2013025. 2013
  7. doi request reprint Acute myeloid leukaemia in adults
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Naples, Italy
    Lancet 381:484-95. 2013
  8. ncbi request reprint Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission
    F Ferrara
    Divisione di Ematologia, Ospedale Cardarelli, Napoli, Italy
    Haematologica 86:814-20. 2001
  9. ncbi request reprint Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Hematol J 5:222-6. 2004
  10. ncbi request reprint Unanswered questions in acute myeloid leukaemia
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy
    Lancet Oncol 5:443-50. 2004

Detail Information

Publications70

  1. ncbi request reprint Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation
    Franco Leoni
    Divisione di Ematologia, Policlinico di Careggi, Viale Morgagni 85, 50134 Florence, Italy
    Haematologica 87:485-9. 2002
    ..The aim of this study was to evaluate the efficacy and toxicity as well as the eligibility to stem cell transplantation (SCT) in a series of 7 patients with relapsing APL, managed with ATO...
  2. ncbi request reprint High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy
    Br J Haematol 128:234-41. 2005
    ..Our data show that a conditioning regimen based on high-dose IDA plus busulphan results in an encouraging reduction of the relapse rate after ASCT in AML...
  3. ncbi request reprint Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
    Roberto Cairoli
    Division of Hematology, Ospedale Niguarda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy
    Blood 107:3463-8. 2006
    ..126) and OS (P = .474) was observed between the c-KIT mutated other than TKD(816) (n = 7) and the c-KIT(-) patients. These findings indicate that c-KIT TKD(816) mutation has a negative impact on the outcome of AML with t(8;21)...
  4. ncbi request reprint Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, A Cardarelli Hospital, Naples, Italy
    Hematol Oncol 24:73-7. 2006
    ..Alternative preparative regimens, allogeneic SCT and/or monoclonal antibodies in the post-ASCT phase should be considered for RR patients despite CR achievement...
  5. ncbi request reprint Clinically useful prognostic factors in acute myeloid leukemia
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Crit Rev Oncol Hematol 66:181-93. 2008
    ....
  6. pmc Physician's Attitude Towards Treatment of Older Patients and the Choice of Therapy
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Mediterr J Hematol Infect Dis 5:e2013025. 2013
    ..Several predictive score have been proposed in order to prevent toxicity in absence of survival advantage; however in the daily practice patients' and physician attitude does still play a major role in the final therapeutic decision...
  7. doi request reprint Acute myeloid leukaemia in adults
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Naples, Italy
    Lancet 381:484-95. 2013
    ..The goal is to target the molecular abnormalities identified at diagnosis; however, several aberrations can coexist in subclones of acute myeloid leukaemia, making the disease less likely to be inhibited by a single agent...
  8. ncbi request reprint Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission
    F Ferrara
    Divisione di Ematologia, Ospedale Cardarelli, Napoli, Italy
    Haematologica 86:814-20. 2001
    ....
  9. ncbi request reprint Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Hematol J 5:222-6. 2004
    ..The aim of this study was to explore the feasibility and safety of performing ASCT on an outpatient basis, according to an early discharge method...
  10. ncbi request reprint Unanswered questions in acute myeloid leukaemia
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy
    Lancet Oncol 5:443-50. 2004
    ..Furthermore, some pivotal questions about the procedures of induction and postinduction therapy of AML remain unanswered, and substantial controversy exists on the optimum therapeutic approach for the disorder...
  11. ncbi request reprint Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation
    F Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, A Cardarelli Hospital, Naples, Italy
    Bone Marrow Transplant 34:573-6. 2004
    ..Our data demonstrate the feasibility of a conditioning regimen based on high-dose idarubicin plus busulfan in elderly AML patients. Results concerning reduction of relapse rate need confirmation in a larger series with longer follow-up...
  12. ncbi request reprint Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy
    Haematologica 89:998-1008. 2004
    ..The biological and clinical characteristics of relapsed AML are analyzed here...
  13. doi request reprint Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy
    Hematol Oncol 27:40-5. 2009
    ..Our data confirm the feasibility of a conditioning regimen based on high-dose idarubicin plus busulphan in older selected AML patients and suggest clinical improvement in patients with normal cytogenetics...
  14. ncbi request reprint Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Anticancer Res 30:3845-9. 2010
    ..Such an approach should also be considered in relapsed patients with an HLA-compatible donor, namely in those with a first CR lasting more than one year or in unfit or elderly individuals...
  15. ncbi request reprint Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Rev Recent Clin Trials 2:33-41. 2007
    ....
  16. ncbi request reprint Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia
    Felicetto Ferrara
    Division of Hematology, Cardarelli Hospital, Naples, Italy
    Haematologica 90:776-84. 2005
    ....
  17. doi request reprint Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy
    Hematol Oncol 26:104-7. 2008
    ..A marked selection is operated as to inclusion into aggressive salvage regimens and only a small minority of patients are offered experimental approaches...
  18. ncbi request reprint Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Leuk Lymphoma 47:1593-8. 2006
    ..It is concluded that APBSCT can result in an improvement of therapeutic results in AML of the elderly, but it is feasible in a minority of selected patients...
  19. doi request reprint Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy
    Hematol Oncol 27:198-202. 2009
    ..We conclude that replacement of oral with intravenous BU results in a more favourable toxicity profile. A longer follow-up is required to assess a potential advantage in terms of disease free survival (DFS)...
  20. doi request reprint Acute promyelocytic leukemia: what are the treatment options?
    Felicetto Ferrara
    Cardarelli Hospital, Division of Hematology and Stem Cell Transplantation Unit, Via Nicolò Piccinni 6, 80128 Napoli, Italy
    Expert Opin Pharmacother 11:587-96. 2010
    ..Since the introduction of all-trans-retinoic-acid in the early 1980s, complete remission rates exceed 90% and the cure rate is > 70%. Notwithstanding, various questions concerning the management of APL remain unanswered...
  21. ncbi request reprint Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura
    F Ferrara
    Division of Hematology, Cardarelli Hospital, Via Niccoló Piccinni 6, 80128 Naples, Italy
    Ann Hematol 81:7-10. 2002
    ..We conclude that VCR is remarkably effective for recurrent thrombotic thrombocytopenic purpura with acceptable toxicity...
  22. ncbi request reprint High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study
    F Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy
    Hematol J 2:214-9. 2001
    ..We investigated the feasibility of a new conditioning regimen consisting of high dose IDA plus oral busulphan in patients undergoing autologous transplantation...
  23. doi request reprint New agents for acute myeloid leukemia: is it time for targeted therapies?
    Felicetto Ferrara
    Cardarelli Hospital, Division of Hematology and Stem Cell Transplantation Unit, Via Nicolò Piccinni 6, 80128 Napoli, Italy
    Expert Opin Investig Drugs 21:179-89. 2012
    ..In addition, mortality due to allogeneic and autologous stem cell transplantation has also been reduced, due to adoption of more effective therapies for graft versus host disease and other transplant-related complications...
  24. doi request reprint Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Hematol Oncol 29:139-43. 2011
    ..The administration of single dose PEG results in no different outcome in terms of safety and efficacy as compared to 8 days of G-CSF...
  25. ncbi request reprint De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG)
    Felicetto Ferrara
    Hematology Division, A O R N A Cardarelli, Naples, Italy
    Eur J Haematol 68:203-9. 2002
    ..To evaluate therapeutic results and prognostic factors from a series of 44 patients affected by de novo acute myeloid leukemia with multilineage dysplasia (MD-AML), treated with the combination of fludarabine, cytarabine and G-CSF (FLAG)...
  26. ncbi request reprint Late relapse of acute promyelocytic leukemia treated with all- trans retinoic acid and chemotherapy: report of two cases
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Via Nicolò Piccinni 6, 80128 Napoli, Italy
    Ann Hematol 83:484-6. 2004
    ..We conclude that, although infrequently, patients with APL treated with modern combination therapy can experience very late relapse and can be rescued with treatment similar to that administered at diagnosis...
  27. doi request reprint Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Clin Lymphoma Myeloma Leuk 11:10-6. 2011
    ..In this perspective, AML in the elderly can represent an ideal target patient population to investigate new AML treatment approaches, that may eventually also be of benefit to younger patients with the disease...
  28. ncbi request reprint Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr
    Felicetto Ferrara
    Divisione di Ematologia, A O R N A Cardarelli, Via Niccoló Piccinni 6, 80126 Naples, Italy
    Eur J Haematol 69:200-4. 2002
    ..The objective of this study was to describe the disease characteristics and treatment results from a series of 22 elderly AML patients undergoing ASCT...
  29. doi request reprint Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Hematol Oncol 28:202-8. 2010
    ..CI-FLA is effective in elderly patients with AML secondary to previously diagnosed MDS. Best results are achievable in the subgroup of patients with diploid karyotype...
  30. ncbi request reprint Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22)
    Felicetto Ferrara
    Division of Hematology, Cardarelli General Hospital, Via Niccoló Piccinni 6, Naples 80128, Italy
    Hematol J 4:218-21. 2003
    ..This case adds further evidence for a specific role of G-CSF in the treatment of AML with t(8;21), namely in patients who are not eligible for aggressive chemotherapy...
  31. doi request reprint Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Via Nicolò Piccinni 6, Naples, Italy
    Am J Hematol 85:687-90. 2010
    ..When compared with conventional DI, it offers the potential to avoid unnecessary toxicity in a consistent proportion of patients...
  32. ncbi request reprint Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients
    Felicetto Ferrara
    Via Nicolò Piccinni 6, 80128, Napoli, Italy
    Anticancer Res 30:967-71. 2010
    ..However, when CR is achieved, a personalized consolidation approach can be adopted with the possibility of achieving long-term disease control...
  33. doi request reprint Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Biol Blood Marrow Transplant 16:1018-24. 2010
    ....
  34. ncbi request reprint Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia
    Felicetto Ferrara
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Biol Blood Marrow Transplant 12:981-6. 2006
    ..43. We conclude that the FLT3 mutations have no influence on mobilization of CD34(+) cells or on feasibility of PBASCT in patients with AML and normal karyotype...
  35. ncbi request reprint Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma
    Mario Annunziata
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Ann Hematol 85:394-9. 2006
    ..01). We conclude that an outpatient combination of VNB plus intermediate dose Cy plus G-CSF is a safe, predictable, and highly effective mobilization regimen for patients with newly-diagnosed MM...
  36. ncbi request reprint Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype
    Salvatore Palmieri
    Division of Haematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Hematol Oncol 25:1-5. 2007
    ..However, it is to consider that autografted patients are highly selected for best response to induction, consolidation and mobilization, as well as for minor non-haematologic toxicity...
  37. ncbi request reprint Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma
    Barbara Pocali
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy
    Leuk Lymphoma 45:1605-9. 2004
    ..Our results demonstrate that treatment with IEV regimen is effective in refractory or relapsing aggressive NHL, resulting in a high percentage of successful stem cell mobilization and feasibility of ASCT...
  38. ncbi request reprint High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21)
    Salvatore Palmieri
    Division of Hematology, Cardarelli Hospital, Naples, Italy
    Leuk Res 26:539-43. 2002
    ..Survival at 5 years is projected at 79%. Our data confirm the efficacy of repeated courses of HDARAC for patients with t(8;21) AML...
  39. doi request reprint Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients
    Andrea Camera
    Hematology, Universita Federico II, Naples, Italy
    Ann Hematol 88:151-8. 2009
    ....
  40. ncbi request reprint Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia
    Ettore Mariano Schiavone
    Division of Hematology and Stem Cell Transplantation Unit, Blood Transfusion Service, A O R N A Cardarelli, Napoli, Italy
    Eur J Haematol 71:23-8. 2003
    ..The objective of this study was to describe the clinical characteristics and treatment results from a series of 32 patients managed with a therapeutic program based on the combination of fludarabine and cyclophosphamide (CTX)...
  41. ncbi request reprint Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia
    Felicetto Ferrara
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Hematol Oncol 25:84-9. 2007
    ..67). Finally, no correlation was found between age and total number of CD34+ cells collected (r = 0.003, p = 0.58). We conclude that age has no impact on mobilization of PBSCs in AML...
  42. ncbi request reprint An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia
    Assunta Viola
    Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    Eur J Haematol 78:41-7. 2007
    ..Finally, neutrophil and platelet recovery after ASCT were comparable between the two groups. An antecedent diagnosis of RAEB has no impact on mobilization and collection of PBSCs in AML as well as on hematopoietic recovery after ASCT...
  43. doi request reprint Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
    Gaetano Corazzelli
    Haematology Oncology and Stem Cell Transplantation Unit, Department of Haematology, Fondazione G Pascale, IRCCS, Naples, Italy
    Br J Haematol 160:207-15. 2013
    ....
  44. ncbi request reprint Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation
    Alessandra Trojani
    Division of Hematology, Niguarda Hospital, Milan, Italy
    Anticancer Res 28:2745-51. 2008
    ..The aim of this study was to investigate if PDGFR mutations are involved in CBFL...
  45. doi request reprint M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience
    Alessandro Pulsoni
    Division of Hematology, Dipartimento di Biotecnologie Cellulari ed Ematologia, La Sapienza University, Via Benevento 6, 00161 Rome, Italy
    Haematologica 93:1025-32. 2008
    ..The aim of this study was to analyze the incidence and prognostic role of these factors in a large series of patients...
  46. ncbi request reprint Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma
    Felicetto Ferrara
    Dipartimento Oncoematologico, Ospedale Cardarelli, Naples, Italy
    Clin Drug Investig 28:55-65. 2008
    ..The aim of this study was to compare the efficacy (survival) and direct medical costs of two chemotherapy regimens, R-CHOP and CHOP, in the treatment of DLBCL in young patients with a good prognosis...
  47. doi request reprint Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia
    Marina Tarsitano
    Service of Medical Genetics, Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy
    Cancer Genet Cytogenet 195:164-7. 2009
    ..The changes in the 11q13 region have been described in both myeloid and lymphoid neoplasm with different chromosomes serving as donors in translocation, but to the best of our knowledge, never with the chromosome 14...
  48. ncbi request reprint HFE gene mutations in patients with acute leukemia
    Assunta Viola
    Divison of Hematology and Stem Cell Transplantion Unit, Cardarelli Hospital, Naples, Italy
    Leuk Lymphoma 47:2331-4. 2006
    ..02). In conclusion, our data demonstrate a correlation between the presence of the H63D mutation and the occurrence of ALL in adult patients...
  49. ncbi request reprint Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients
    Giovanni D'Arena
    Hematology, Oncology and Bone Marrow Transplantation Unit, National Cancer Institute, Fondazione Pascale, Naples, Italy
    Eur J Haematol 79:53-8. 2007
    ..In conclusion, our experience clearly demonstrates that anti-CD20 monoclonal antibody rituximab is an effective and safe alternative treatment option for idiopathic AIHA, in particular, for steroid-refractory disease...
  50. pmc HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b
    Ilaria Lepore
    Department of Biochemistry, Biophysics and General Pathology, Seconda Universita degli Studi di Napoli, Naples, Italy
    PLoS ONE 8:e83018. 2013
    ..Moreover, we identify a specific BARD1 isoform, which might act as tumor diagnostic and prognostic markers. ..
  51. ncbi request reprint Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity
    Felicetto Ferrara
    Divisione di Ematologia, Ospedale A Cardarelli, Naples, Italy
    Haematologica 87:306-19. 2002
    ..We focus on recent advances on biology and treatment of AML with t(8;21)...
  52. pmc Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation
    Enrica Morra
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Haematologica 94:102-12. 2009
    ..We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL acute myeloid leukemia...
  53. ncbi request reprint Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia
    Giovanni D'Arena
    Hematology and Bone Marrow Transplantation Unit, National Cancer Institute, IRCCS Fondazione G Pascale, Naples, Italy
    Am J Hematol 81:598-602. 2006
    ..At a mean follow-up of 17 months, 8 patients were still alive, 6 of them transfusion-free. Our results prove that the anti-CD20 monoclonal antibody is an effective and well-tolerated alternative treatment for CLL-associated AIHA...
  54. ncbi request reprint Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
    Angela Nebbioso
    Dipartimento di Patologia Generale, Seconda Universita degli Studi di Napoli, Vico Luigi de Crecchio 7, 80138, Napoli, Italy
    Nat Med 11:77-84. 2005
    ..No apoptosis was seen in normal CD34(+) progenitor cells. Our results identify TRAIL as a mediator of the anticancer action of HDACIs...
  55. ncbi request reprint A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol
    Marco Mancini
    Department of Cellular Biotechnologies and Hematology, University La Sapienza Via Benevento 6 Rome, 00161 Italy
    Blood 105:3434-41. 2005
    ....
  56. ncbi request reprint Efficacy and safety of bortezomib in patients with plasma cell leukemia
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, CROB Reference Cancer Center of Basilicata, Rionero in Vulture PZ, Italy
    Cancer 109:2285-90. 2007
    ..Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of bortezomib in PCL is scanty and derives from anecdotal, single-case reports...
  57. ncbi request reprint Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol
    Antonella Vitale
    Department of Cellular Biotechnologies and Hematology, University La Sapienza Roma, Rome, Italy
    Blood 107:473-9. 2006
    ..An extensive biologic workup of adult T-ALL cases at presentation is recommended in order to design tailored therapeutic strategies aimed at improving CR rates...
  58. ncbi request reprint Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adu
    Marco Vignetti
    Department of Cellular Biotechnologies and Hematology, La Sapienza University, Via Benevento 6, 00161 Rome, Italy
    Blood 109:3676-8. 2007
    ....
  59. ncbi request reprint Evaluation of leukemic contamination in peripheral blood stem cell leukaphereses vs bone marrow after consolidation therapy in acute myeloid leukemia: not a critical factor in outcome?
    Lorella Melillo
    Hematology and Stem Cell Unit, IRCCS Casa Sollievo della Sofferenza, S Giovanni Rotondo FG, Italy
    Haematologica 88:715-8. 2003
  60. ncbi request reprint Therapy-related acute myeloid leukemia with t(9;11)(p12;q23) in a patient treated for acute promyelocytic leukemia
    Mario Annunziata
    Hematol J 4:289-91. 2003
  61. ncbi request reprint Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study
    Luciana Annino
    Department of Cellular Biotechnology and Hematology, Universita degli Studi La Sapienza, via Benevento, 6 00161, Rome, Italy
    Blood 99:863-71. 2002
    ..Neither induction intensification nor early consolidation appeared to influence CCR and DFS duration. For the first time PDN pretreatment response proved to be a powerful factor predicting disease outcome in adult ALL patients...
  62. ncbi request reprint Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia
    Felicetto Ferrara
    Haematologica 89:621-2. 2004
    ..After a median follow-up of 33 months from ASCT, 5 patients are alive in molecular remission and one died 27 months after autograft from refractory relapse...
  63. ncbi request reprint Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow
    Giuseppe Avvisati
    Hematology, Università Campus Bio Medico, 83 Via Emilio Longoni, 00155 Rome, Italy
    Blood 100:3141-6. 2002
    ..0001) and increasing age (P =.0251). These results indicate that anthracycline monochemotherapy with IDA favorably influences the EFS of patients with newly diagnosed hypergranular APL...
  64. ncbi request reprint The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes
    Francesco Albano
    Department of Hematology, University of Bari, Italy
    Haematologica 91:311-6. 2006
    ..To date, it is still not clear whether CD34 expression identifies a subset of APL patients with peculiar characteristics. We, therefore, conducted a detailed analysis of CD34 expression at diagnosis in 136 adults with de novo APL...
  65. ncbi request reprint Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities
    Paola Bontempo
    Dipartimento di Patologia Generale, Seconda Universita degli Studi di Napoli, Vico L De Crecchio 7, 80138 Napoli, Italy
    Int J Biochem Cell Biol 39:1902-14. 2007
    ....
  66. ncbi request reprint Conservative treatment for patients over 80 years with acute myelogenous leukemia
    Roberto Latagliata
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza of Rome
    Am J Hematol 71:256-9. 2002
    ....
  67. doi request reprint R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study
    Giuseppe Visani
    Hematology and Hematopoietic Stem Cell Transplant Center, San Salvatore Hospital, Pesaro, Italy
    Leuk Lymphoma 49:1081-6. 2008
    ..In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma...
  68. ncbi request reprint MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
    Agostino Tafuri
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Roma, Italy
    Blood 100:974-81. 2002
    ..MDR1 expression did not correlate with CR duration, nor did it predict for survival duration. These results demonstrate that MDR1 expression in de novo adult ALL is an independent predictor of CR achievement...
  69. doi request reprint Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
    Francesco Zaja
    Clinica Ematologica, Azienda Ospedaliera Universitaria, piazza S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 93:930-3. 2008
    ..After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose...
  70. doi request reprint Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia
    Pellegrino Musto
    Cancer 113:1995-8. 2008